Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13109032 | 0.85 | MEN1 (0.60) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL17079761 | 0.85 | MEN1 (0.60) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL14631440 | 0.83 | MEN1 (0.45) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL7442826 | 0.82 | MEN1 (0.44) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL25867173 | 0.81 | MEN1 (0.46) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL6200616 | 0.79 | MEN1 (0.64) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL6200619 | 0.79 | MEN1 (0.64) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL18350271 | 0.79 | MEN1 (0.47) | MEN1KMT2AGAACTSKTDP1 | |
| SCHEMBL26522489 | 0.79 | CPB2 (0.49) | CPB2ZDHHC7MAPTCA2CA1 | |
| SCHEMBL25243412 | 0.78 | MEN1 (0.41) | MEN1KMT2AGAACTSKTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-106232617-B | Polymyxin derivatives and their use in combination therapy with different antibiotics | 云顶新耀医药科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3116897-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3116897-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | New Pharma Licence Holdings Limited (MT) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015135976-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015135976-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | MEN1 1690/4885KMT2A 3363/4885GAA 2991/4885 |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | MEN1 1690/4885KMT2A 3363/4885GAA 2991/4885 |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | MEN1 1766/4885KMT2A 3642/4885GAA 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.